Scholarlink

<p>Gastrointestinal stromal tumors (GISTs) with <i>platelet-derived growth factor receptor alpha</i> (<i>PDGFRA</i>) mutations are resistant to tyrosine kinase inhibitors. Pimitespib, a novel heat shock protein 90 inhibitor, was recently approved as a fourth-line treatment for advanced GISTs; however, data on its efficacy against <i>PDGFRA</i>-mutant GISTs remain scarce. We report a case of a 67-year-old male with a gastric GIST harboring a <i>PDGFRA</i> exon 18 Asp842Val mutation. The patient presented with a large peritoneal metastasis at the hepatic hilum and underwent proton beam therapy, achieving 8 months of disease control. However, the tumor progressed thereafter. Regorafenib was introduced but failed immediately owing to tumor penetration. The treatment was switched to pimitespib (160&#xa0;mg daily, 5 days on, 2 days off, per 21-day cycle), and the patient completed four cycles of the therapy. Post-treatment <sup>18</sup>F-fluorodeoxyglucose (FDG)-positron emission tomography showed a significant reduction in FDG uptake by the metastatic lesion. Pimitespib therapy was eventually discontinued because of duodenal bleeding, with a time to treatment failure of 13&#xa0;weeks. Although based on a single case, this report demonstrates a significant metabolic response to pimitespib in <i>PDGFRA</i>-mutant GIST. More cases are required to fully elucidate the efficacy of this therapy against such rare tumors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pimitespib therapy for a patient with PDGFRA D842V-mutant gastrointestinal stromal tumor

  • 期刊论文

  • 发表日期：

    2025年5月10日

查看全文
  • Tatsuo Kanda,
  • Masafumi Ishikawa,
  • Kae Techigawara,
  • Toshiyuki Saginoya,
  • Koichi Hamada,
  • Motonobu Saito,
  • Noriyuki Uesugi,
  • Yasushi Teranishi

摘要

Gastrointestinal stromal tumors (GISTs) with platelet-derived growth factor receptor alpha (PDGFRA) mutations are resistant to tyrosine kinase inhibitors. Pimitespib, a novel heat shock protein 90 inhibitor, was recently approved as a fourth-line treatment for advanced GISTs; however, data on its efficacy against PDGFRA-mutant GISTs remain scarce. We report a case of a 67-year-old male with a gastric GIST harboring a PDGFRA exon 18 Asp842Val mutation. The patient presented with a large peritoneal metastasis at the hepatic hilum and underwent proton beam therapy, achieving 8 months of disease control. However, the tumor progressed thereafter. Regorafenib was introduced but failed immediately owing to tumor penetration. The treatment was switched to pimitespib (160 mg daily, 5 days on, 2 days off, per 21-day cycle), and the patient completed four cycles of the therapy. Post-treatment 18F-fluorodeoxyglucose (FDG)-positron emission tomography showed a significant reduction in FDG uptake by the metastatic lesion. Pimitespib therapy was eventually discontinued because of duodenal bleeding, with a time to treatment failure of 13 weeks. Although based on a single case, this report demonstrates a significant metabolic response to pimitespib in PDGFRA-mutant GIST. More cases are required to fully elucidate the efficacy of this therapy against such rare tumors.